

Results of individual trials (2018 December update)

Overall survival (OS) and progression-free survival (PFS)

Trials	Treatment (arm 1)	Treatment (arm 2)	OS,HR (95%CI)	PFS,HR (95%CI)
ARCHER 1009, 2014	Dacomitinib	Erlotinib	1.03(0.89-1.19)	0.93(0.80-1.10)
ARQ 197-209, 2011	Erlotinib+Tivantinib	Erlotinib	0.87(0.59-1.27)	0.74(0.51-1.06)
ATTENTION, 2015	Erlotinib+Tivantinib	Erlotinib	0.89(0.67-1.18)	0.72(0.54-0.95)
Bergqvist, 2014	AXL1717	Docetaxel	1.10(0.80-1.50)	1.30(0.83-2.02)
Besse, 2014	Erlotinib+Everolimus	Erlotinib	1.28(0.69-2.37)	0.77(0.51-1.17)
BeTa, 2011	Erlotinib+Bevacizumab	Erlotinib	0.97(0.8-1.18)	0.62(0.52-0.75)
Bhatnagar, 2012	Docetaxel	Gefitinib	-	-
Blumenschein, 2015	Docetaxel	Trametinib	0.97(0.52-1.83)	1.23(0.81-1.87)
BR21, 2005	Erlotinib	Placebo	0.73(0.60-0.87)	0.61(0.51-0.73)
CALGB 30704, 2014	Sunitinib	Pemetrexed	1.40(0.90-2.30)	1.40(0.90-2.20)
CALGB 30704, 2014	Pemetrexed+Sunitinib	Sunitinib	2.00(1.20-3.20)	1.30(0.90-2.10)
CheckMate017, 2015	Nivolumab	Docetaxel	0.62(0.47-0.8)	0.63(0.48-0.82)
CheckMate057, 2015	Nivolumab	Docetaxel	0.75(0.63-0.91)	0.89(0.74-1.06)
Chen, 2011	Tegafur/uracil+Gefitinib	Gefitinib	0.82 (0.48-1.40)	0.65(0.43-0.97)
CTONG0806, 2014	Pemetrexed	Gefitinib	0.72(0.49-1.04)	0.53(0.38-0.75)
Dai, 2013	Gefitinib	Pemetrexed	-	0.77(0.42-1.43)
DATE, 2015	Gefitinib+Nimotuzumab	Gefitinib	0.86(0.57-1.30)	1.03(0.71-1.41)
DELTA, 2014	Erlotinib	Docetaxel	0.91(0.68-1.22)	1.22(0.97-1.55)
Dittrich, 2014	Pemetrexed+Erlotinib	Pemetrexed	0.68(0.47-0.98)	0.63(0.44-0.90)
E1512, 2015	Cabozantinib	Erlotinib	0.68(0.33-1.03)	0.39(0.17-0.61)
E1512, 2015	Erlotinib+Cabozantinib	Erlotinib	0.51(0.22-0.80)	0.37(0.15-0.58)
Esteban, 2003	Paclitaxel	Docetaxel	1.84 (1.12-3.02)	-
Gerber, 2014	Erlotinib+Tivantinib	Chemotherapy	1.07(0.66-1.74)	1.19(0.71-1.97)
GFPC 05-06, 2011	Pemetrexed	Docetaxel	0.85(0.61-1.20)	0.93(0.67-1.29)
Groen, 2013	Erlotinib+Sunitinib	Erlotinib	1.07(0.71-1.61)	0.90(0.46-1.76)
Hainsworth, 2010	Selumetinib	Pemetrexed	-	1.08(0.62-1.86)
Han, 2011	Pemetrexed	Docetaxel	-	-
HANSHIN, 2015	Docetaxel+Bevacizumab	S1+Bevacizumab	1.25(0.73-2.14)	0.84(0.53-1.32)
Herbst, 2007	Chemotherapy+Bevacizumab	Chemotherapy	0.71(0.41-1.21)	0.66(0.38-1.16)
Herbst, 2007	Erlotinib+Bevacizumab	Chemotherapy	0.78(0.46-1.31)	0.72(0.42-1.23)
Heymach, 2007	Docetaxel+Vandetanib	Docetaxel	0.91(0.55-1.52)	0.64(0.38-1.05)
HORG, 2013	Pemetrexed	Erlotinib	0.99(0.78-1.29)	-

Hosomi, 2015	Docetaxel+Ramucirumab	Docetaxel	0.86 (0.56-1.32)	0.83(0.59-1.16)
ICOGN, 2013	Icotinib	Gefitinib	1.02(0.82-1.27)	0.84(0.67-1.05)
INTEREST, 2008	Gefitinib	Docetaxel	1.02(0.91-1.14)	1.04(0.93-1.16)
ISEL, 2005	Gefitinib	Placebo	0.89(0.77-1.02)	-
ISTANA, 2010	Gefitinib	Docetaxel	0.87(0.61-1.24)	0.73(0.50-1.06)
Janne, 2013	Docetaxel+Selumetinib	Docetaxel	0.81(0.48-1.36)	0.58(0.36-0.94)
JMEI, 2004	Pemetrexed	Docetaxel	0.99(0.82-1.20)	0.97(0.82-1.16)
Jones, 2008	Topotecan	Docetaxel	0.79 (0.50-1.25)	-
Juan, 2014	Docetaxel+Erlotinib	Erlotinib	0.70(0.41-1.19)	0.65(0.39-1.06)
Kapoor, 2015	Gefitinib	Docetaxel	0.89(0.49-1.29)	1.12(0.77-1.45)
Katakami, 2014	Amrubicin	Docetaxel	1.02(0.72-1.43)	0.96(0.69-1.34)
KCSG-LU08-01, 2012	Gefitinib	Pemetrexed	0.80(0.50-1.30)	0.54(0.37-0.79)
Kelly, 2012	Pralatrexate	Erlotinib	0.83(0.61-1.13)	0.91(0.63-1.32)
KEYNOTE-010,2015	Pembrolizumab	Docetaxel	0.71(0.58-0.88)	0.88(0.73-1.04)
Kim A, 2012	Pemetrexed+Cetuximab	Pemetrexed	1.01(0.86-1.20)	1.03(0.87-1.21)
Kim B, 2012	Docetaxel+Cetuximab	Docetaxel	1.13(0.90-1.41)	0.91(0.73-1.13)
Kim, 2015	Pemetrexed	Gefitinib	0.98(0.64-1.50)	0.96(0.64-1.44)
Krzakowski, 2010	Vinflunine	Docetaxel	0.97(0.81-1.18)	1.00(0.84-1.12)
Kuo, 2013	Docetaxel	Gefitinib	-	-
Lee, 2013	Pemetrexed+Erlotinib	Erlotinib	1.08(0.69-1.67)	0.57(0.40-0.81)
Lee, 2013	Pemetrexed+Erlotinib	Pemetrexed	0.75(0.49-1.13)	0.58(0.39-0.85)
Lee, 2013	Erlotinib	Pemetrexed	0.69(0.45-1.06)	1.01(0.71-1.43)
Levy, 2014	Docetaxel+PX-866	Docetaxel	1.49 (0.90-2.48)	1.08 (0.71-1.63)
Li, 2010	Gefitinib	Docetaxel	0.97(0.63-1.49)	-
Li, 2012	Pemetrexed	Docetaxel	-	-
Li, 2013	Pemetrexed+Erlotinib	Pemetrexed	0.71(0.42-1.11)	0.63(0.40-1.00)
Li, 2014	Erlotinib	Pemetrexed	1.01(0.66-1.54)	0.92(0.62-1.37)
Liu, 2015	Nab-Paclitaxel	Pemetrexed	1.23(0.78-1.59)	1.12(0.69-1.31)
LUME-COLUMBUS,2016	Docetaxel+Nintedanib	Docetaxel	-	-
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	Docetaxel	0.94(0.83-1.05)	0.85(0.75-0.96)
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	Pemetrexed	1.01(0.85-1.21)	0.84(0.70-1.00)
Lux-Lung 8, 2015	Afatinib	Erlotinib	0.81(0.69-0.95)	0.82(0.68-0.99)
Maitland, 2014	Pemetrexed+Cetuximab	Cetuximab	0.63(0.32-1.26)	0.59(0.32-1.10)
Marangolo, 2000	Docetaxel	Vinorelbine	-	-
MARQUEE, 2013	Erlotinib+Tivantinib	Erlotinib	0.98(0.84-1.14)	0.74(0.64-0.85)
MARVEL, 2013	Erlotinib	Pemetrexed	-	-
METLung, 2014	Erlotinib+Onartuzumab	Erlotinib	1.27(0.98-1.65)	1,08(0.85-1.08)
Moran, 2014	Erlotinib+Dalotuzumab	Erlotinib	1.80(0.87-3.72)	0.86(0.47-1.57)

Natale, 2009	Vandetanib	Gefitinib	1.19(0.84-1.68)	0.69(0.50-0.96)
NCCTG N0626, 2011	Pemetrexed+Sorafenib	Pemetrexed	-	-
NCIC CTG BR.26, 2014	Dacomitinib	Placebo	1.00(0.83-1.21)	0.66(0.55-0.79)
NVALT-10, 2013	Erlotinib+Chemotherapy	Erlotinib	0.67(0.49-0.91)	0.76(0.58-1.02)
OAK,2016	Atezolizumab	Docetaxel	0.8 (0.7-0.92)	0.96 (0.85-1.08)
Paz-Ares, 2008	Docetaxel	Paclitaxel	1.09(0.94-1.27)	-
POPLAR, 2016	Atezolizumab	Docetaxel	0.69(0.52-0.92)	0.94(0.72-1.23)
PROSE, 2014	Chemotherapy	Erlotinib	1.14(0.88-1.49)	1.27(0.99-1.62)
Ramalingam, 2011	Erlotinib+R1507	Erlotinib	0.72(0.50-1.04)	0.93(0.64-1.36)
Ramalingam, 2012	Dacomitinib	Erlotinib	0.82(0.59-1.15)	0.66(0.47-0.91)
Ramlau, 2006	Topotecan	Docetaxel	1.16(1.00-1.35)	-
Ramlau, 2012	Docetaxel+Aflibercept	Docetaxel	1.01(0.87-1.17)	0.82(0.72-0.94)
REVEL, 2014	Docetaxel+Ramucirumab	Docetaxel	0.86(0.75-0.98)	0.76(0.68-0.86)
Sbar, 2010	Erlotinib	BMS-690514	-	-
Scagliotti, 2012	Erlotinib+Sunitinib	Erlotinib	0.94(0.82-1.08)	0.81(0.70-0.94)
Scagliotti, 2014	Erlotinib+Figitumumab	Erlotinib	1.09(0.91-1.31)	1.08(0.90-1.29)
Schiller, 2010	Pemetrexed+Matuzumab	Pemetrexed	1.66(0.97-2.86)	1.46(0.90-2.38)
SELECT 1,2017	Docetaxel+Selumetinib	Docetaxel	1.05 (0.85-1.30)	0.93 (0.77-1.12)
SIGN, 2006	Gefitinib	Docetaxel	0.97(0.61-1.52)	0.94(0.64-1.39)
Spigel, 2011	Erlotinib+Sorafenib	Erlotinib	0.89(0.59-1.34)	0.86(0.60-1.22)
Spigel, 2012	Erlotinib+Pazopanib	Erlotinib	1.10(0.77-1.55)	0.59(0.43-0.83)
Spigel, 2013	Erlotinib+Onartuzumab	Erlotinib	0.80(0.50-1.28)	1.09(0.73-1.62)
Sun, 2013	Pemetrexed	Docetaxel	1.02(0.74-1.40)	1.05(0.75-1.46)
TAILOR, 2013	Docetaxel	Erlotinib	0.78(0.51-1.05)	0.72(0.55-0.94)
TALISMAN, 2015	Docetaxel+Erlotinib	Erlotinib	0.87 (0.51-1.48)	0.96 (0.58-1.58)
TAX 317, 2000	Docetaxel	Placebo	0.56(0.35-0.88)	-
TITAN, 2012	Erlotinib	Chemotherapy	0.96(0.78-1.19)	1.19(0.97-1.46)
TORI L-03, 2013	Erlotinib+Fulvestrant	Erlotinib	0.96(0.60-1.55)	0.85(0.55-1.33)
ULTIMATE, 2016	Paclitaxel+Bevacizumab	Docetaxel	1.25 (0.88-1.78)	0.62 (0.44-0.87)
V15-32, 2008	Gefitinib	Docetaxel	1.12(0.89-1.40)	0.90(0.72-1.12)
Wen, 2016	Docetaxel+Tamoxifen	Docetaxel	0.72(0.48-1.06)	0.67(0.45-0.96)
Witta, 2012	Entinostat+Erlotinib	Erlotinib	0.85(0.59-1.23)	0.99(0.68-1.44)
WJOG 5108L, 2016	Gefitinib	Erlotinib	1.03(0.83-1.29)	1.07(0.89-1.28)
ZEAL, 2011	Pemetrexed+Vandetanib	Pemetrexed	0.86(0.68-1.09)	0.86(0.71-1.04)
ZEST, 2011	Vandetanib	Erlotinib	1.01(0.89-1.15)	0.98(0.87-1.10)
Zhang, 2015	Nab-Paclitaxel+Erlotinib	Erlotinib	0.68(0.25-0.81)	0.24(0.14-0.74)
ZODIAC, 2010	Docetaxel+Vandetanib	Docetaxel	0.91(0.79-1.04)	0.79(0.71-0.88)
<i>East Asia S-1 Trial in Lung Cancer,</i>	<i>S-1</i>	<i>Docetaxel</i>	<i>0.95(0.83-1.07)</i>	<i>1.03(0.91-1.17)</i>

2017				
Fandi, 2018	<i>CC-486 + Pembrolizumab</i>	<i>Pembrolizumab</i>	<i>1,38(0.83-2.78)</i>	<i>1.35(0.91-2.00)</i>
SELECT-2, 2017	<i>Selumetinib + docetaxel 60</i>	<i>Docetaxel 75</i>	<i>1,43(0.97-2.13)</i>	<i>1.12(0.8-1.61)</i>
SELECT-2, 2017	<i>Selumetinib + docetaxel 75</i>	<i>Docetaxel 75</i>	<i>1,18(0.80-1.78)</i>	<i>0.92(0.65-1.31)</i>
Wu, 2017	<i>Nab-paclitaxel</i>	<i>Placebo</i>	<i>0.71(0.30-0.85)</i>	<i>0.62(0.33-0.81)</i>
Yu, 2018	<i>Apatinib+ Chemotherapy</i>	<i>Chemotherapy</i>	<i>NA</i>	<i>NA</i>
JAVELIN, 2018	<i>Avelumab</i>	<i>Docetaxel</i>	<i>0.9(0.75-1.08)</i>	<i>1.16(0.97-1.4)</i>
ABOUND 2L+, 2018	<i>Nab-Paclitaxel+CC-486</i>	<i>Nab-Paclitaxel</i>	<i>1.7(1.08-2.57)</i>	<i>1.3(0.87-1.94)</i>

In blue italic bold are the new results from the 2018 update

Objective response rate (ORR)

Trials	Treatment (arm 1)	ORR	Treatment (arm 2)	ORR	Treatment (arm 3)	ORR
ARCHER 1009, 2014	Dacomitinib	12%	Erlotinib	8%		
ARQ 197-209, 2011	Erlotinib+Tivantinib	8%	Erlotinib	6%		
ATTENTION, 2015	Erlotinib+Tivantinib	8%	Erlotinib	7%		
Bergqvist, 2014	AXL1717	0%	Docetaxel	12%		
Besse, 2014	Erlotinib+Everolimus	12%	Erlotinib	10%		
BeTa, 2011	Erlotinib+Bevacizumab	12%	Erlotinib	6%		
Bhatnagar, 2012	Docetaxel	27%	Gefitinib	33%		
Blumenschein, 2015	Docetaxel	11%	Trametinib	11%		
BR21, 2005	Erlotinib	8%	Placebo	1%		
CALGB 30704, 2014	Pemetrexed+Sunitinib	22%	Sunitinib	17%	Pemetrexed	14%
CheckMate017, 2015	Nivolumab	20%	Docetaxel	9%		
CheckMate057, 2015	Nivolumab	19%	Docetaxel	12%		
Chen, 2011	Tegafur/uracil+Gefitinib	37%	Gefitinib	34%		
CTONG0806, 2014	Pemetrexed	14%	Gefitinib	12%		
Dai, 2013	Gefitinib	17%	Pemetrexed	13%		
DATE, 2015	Gefitinib+Nimotuzumab	17%	Gefitinib	22%		
DELTA, 2014	Erlotinib	17%	Docetaxel	17%		
Dittrich, 2014	Pemetrexed+Erlotinib	16%	Pemetrexed	11%		
E1512, 2015	Cabozantinib	10%	Erlotinib+Cabozantinib	5%	Erlotinib	2%
Esteban, 2003	Paclitaxel	14%	Docetaxel	3%		
Gerber, 2014	Erlotinib+Tivantinib	0%	Chemotherapy	9%		
GFPC 05-06, 2011	Pemetrexed	12%	Docetaxel	11%		
Groen, 2013	Erlotinib+Sunitinib	5%	Erlotinib	3%		
Hainsworth, 2010	Selumetinib	5%	Pemetrexed	5%		
Han, 2011	Pemetrexed	14%	Docetaxel	10%		

HANSHIN, 2015	Docetaxel+Bevacizumab	20%	S1+Bevacizumab	2%		
Herbst, 2007	Erlotinib+Bevacizumab	18%	Chemotherapy+Bev acizumab	13%	Chemotherapy	12%
Heymach, 2007	Docetaxel+Vandetanib	26%	Docetaxel	12%		
HORG, 2013	Pemetrexed	11%	Erlotinib	8%		
Hosomi, 2015	Docetaxel+Ramucirumab	28%	Docetaxel	19%		
ICOGEN, 2013	Icotinib	28%	Gefitinib	27%		
INTEREST, 2008	Gefitinib	8%	Docetaxel	7%		
ISEL, 2005	Gefitinib	7%	Placebo	1%		
ISTANA, 2010	Gefitinib	28%	Docetaxel	8%		
Janne, 2013	Docetaxel+Selumetinib	36%	Docetaxel	0%		
JMEI, 2004	Pemetrexed	8%	Docetaxel	8%		
Jones, 2008	Topotecan	8%	Docetaxel	7%		
Juan, 2014	Docetaxel+Erlotinib	3%	Erlotinib	8%		
Kapoor, 2015	Gefitinib	-	Docetaxel	-		
Katakami, 2014	Amrubicin	14%	Docetaxel	19%		
KCSG-LU08-01, 2012	Gefitinib	44%	Pemetrexed	27%		
Kelly, 2012	Pralatrexate	2%	Erlotinib	7%		
KEYNOTE-010,2015	Pembrolizumab	18%	Docetaxel	9%		
Kim A, 2012	Pemetrexed+Cetuximab	7%	Pemetrexed	4%		
Kim B, 2012	Docetaxel+Cetuximab	8%	Docetaxel	7%		
Kim, 2015	Pemetrexed	13%	Gefitinib	8%		
Krzakowski, 2010	Vinflunine	4%	Docetaxel	5%		
Kuo, 2013	Docetaxel	-	Gefitinib	-		
Lee, 2013	Pemetrexed+Erlotinib	44%	Erlotinib	29%	Pemetrexed	10%
Levy, 2014	Docetaxel+PX-866	6%	Docetaxel	0%		
Li, 2010	Gefitinib	22%	Docetaxel	19%		
Li, 2012	Pemetrexed	8%	Docetaxel	4%		

Li, 2013	Pemetrexed+Erlotinib	27%	Pemetrexed	11%
Li, 2014	Erlotinib	20%	Pemetrexed	8%
Liu, 2015	Nab-Paclitaxel	15%	Pemetrexed	11%
LUME-COLUMBUS, 2016	Docetaxel+Nintedanib	-	Docetaxel	-
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	4%	Docetaxel	3%
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	9%	Pemetrexed	8%
Lux-Lung 8, 2015	Afatinib	4%	Erlotinib	3%
Maitland, 2014	Pemetrexed+Cetuximab	13%	Cetuximab	0%
Marangolo, 2000	Docetaxel	7%	Vinorelbine	0%
MARQUEE, 2013	Erlotinib+Tivantinib	10%	Erlotinib	7%
MARVEL, 2013	Erlotinib	-	Pemetrexed	-
METLung, 2014	Erlotinib+Onartuzumab	6%	Erlotinib	9%
Moran, 2014	Erlotinib+Dalotuzumab	3%	Erlotinib	8%
Natale, 2009	Vandetanib	8%	Gefitinib	1%
NCCTG N0626, 2011	Pemetrexed+Sorafenib	13%	Pemetrexed	10%
NCIC CTG BR.26, 2014	Dacomitinib	7%	Placebo	1%
NVALT-10, 2013	Erlotinib+Chemotherapy	13%	Erlotinib	7%
OAK, 2016	Atezolizumab	14%	Docetaxel	12%
Paz-Ares, 2008	Docetaxel	12%	Paclitaxel	8%
POPLAR, 2016	Atezolizumab	15%	Docetaxel	15%
PROSE, 2014	Chemotherapy	9%	Erlotinib	7%
Ramalingam, 2011	Erlotinib+R1507	7%	Erlotinib	9%
Ramalingam, 2012	Dacomitinib	17%	Erlotinib	5%
Ramlau, 2006	Topotecan	5%	Docetaxel	5%
Ramlau, 2012	Docetaxel+Aflibercept	21%	Docetaxel	8%

REVEL, 2014	Docetaxel+Ramucirumab	23%	Docetaxel	14%
Sbar, 2010	Erlotinib	-	BMS-690514	-
Scagliotti, 2012	Erlotinib+Sunitinib	11%	Erlotinib	7%
Scagliotti, 2014	Erlotinib+Figitumumab	5%	Erlotinib	4%
Schiller, 2010	Pemetrexed+Matuzumab	2%	Pemetrexed	4%
SELECT 1,2017	Docetaxel+Selumetinib	20%	Docetaxel	14%
SIGN, 2006	Gefitinib	13%	Docetaxel	14%
Spigel, 2011	Erlotinib+Sorafenib	8%	Erlotinib	11%
Spigel, 2012	Erlotinib+Pazopanib	9%	Erlotinib	4%
Spigel, 2013	Erlotinib+Onartuzumab	6%	Erlotinib	4%
Sun, 2013	Pemetrexed	9%	Docetaxel	4%
TAILOR, 2013	Docetaxel	14%	Erlotinib	3%
TALISMAN, 2015	Docetaxel+Erlotinib	8%	Erlotinib	3%
TAX 317, 2000	Docetaxel	5%	Placebo	0%
TITAN, 2012	Erlotinib	8%	Chemotherapy	6%
TORI L-03, 2013	Erlotinib+Fulvestrant	24%	Erlotinib	14%
ULTIMATE, 2016	Paclitaxel+Bevacizumab	23%	Docetaxel	5%
V15-32, 2008	Gefitinib	18%	Docetaxel	10%
Wen, 2016	Docetaxel+Tamoxifen	37%	Docetaxel	15%
Witta, 2012	Entinostat+Erlotinib	3%	Erlotinib	9%
WJOG 5108L, 2016	Gefitinib	40%	Erlotinib	36%
ZEAL, 2011	Pemetrexed+Vandetanib	19%	Pemetrexed	8%
ZEST, 2011	Vandetanib	12%	Erlotinib	12%
Zhang, 2015	Nab-Paclitaxel+Erlotinib	33%	Erlotinib	19%
ZODIAC, 2010	Docetaxel+Vandetanib	17%	Docetaxel	10%

East Asia S-1 Trial in Lung Cancer, 2017	<i>S-1</i>	<i>7%</i>	<i>Docetaxel</i>	<i>9%</i>		
Fandi, 2018	<i>CC-486 + Pembrolizumab</i>	<i>20%</i>	<i>placebo + Pembrolizumab</i>	<i>14%</i>		
SELECT-2, 2017	<i>Selumetinib + docetaxel 60</i>	<i>18%</i>	<i>Selumetinib + docetaxel 75</i>	<i>33%</i>	<i>Placebo + docetaxel 75</i>	<i>14%</i>
Wu, 2018	<i>Nab-paclitaxel</i>	<i>20%</i>	<i>Placebo</i>	<i>4%</i>		
Yu, 2018	<i>Apatinib+ Chemotherapy</i>		<i>Chemotherapy</i>			
JAVELIN, 2018	<i>Avelumab</i>	<i>15%</i>	<i>Docetaxel</i>	<i>11%</i>		
ABOUND 2L+, 2018	<i>Nab-Paclitaxel+CC-486</i>	<i>14%</i>	<i>Nab-Paclitaxel</i>	<i>16%</i>		

Serious adverse events (SAE) 2018 update

Trials	Treatment (arm 1)	SAE (%)	Treatment (arm 2)	SAE (%)	Treatment (arm 3)	SAE (%)
ARCHER 1009, 2014	Dacomitinib	41%	Erlotinib	39%		
Besse, 2014	Erlotinib+Everolimus	41%	Erlotinib	18%		
BeTa, 2011	Erlotinib+Bevacizumab	42%	Erlotinib	36%		
Bhatnagar, 2012	Docetaxel	13%	Gefitinib	0%		
Blumenschein, 2015	Trametinib	37%	Docetaxel	21%		
CALGB 30704, 2014	Pemetrexed+Sunitinib	51%	Sunitinib	40%	Pemetrexed	31%
CheckMate017, 2015	Nivolumab	47%	Docetaxel	54%		
CheckMate057, 2015	Nivolumab	47%	Docetaxel	41%		
Dittrich, 2014	Pemetrexed+Erlotinib	70%	Pemetrexed	52%		
E1512, 2015	Erlotinib+Cabozantinib	72%	Cabozantinib	70%	Erlotinib	33%
Gerber, 2014	Erlotinib+Tivantinib	4%	Chemotherapy	11%		
Groen, 2013	Erlotinib+Sunitinib	45%	Erlotinib	44%		
Hainsworth, 2010	Selumetinib	3%	Pemetrexed	7%		
Herbst, 2007	Chemotherapy+Bevacizumab	41%	Chemotherapy	55%	Erlotinib+Bevacizumab	33%
Hosomi, 2015	Docetaxel+Ramucirumab	32%	Docetaxel	32%		
ICOGEN, 2013	Icotinib	7%	Gefitinib	8%		
INTEREST, 2008	Gefitinib	22%	Docetaxel	29%		
ISTANA, 2010	Docetaxel	25%	Gefitinib	16%		
Janne, 2013	Docetaxel+Selumetinib	84%	Docetaxel	67%		
Katakami, 2014	Amrubicin	15%	Docetaxel	22%		
KCSG-LU08-01, 2012	Pemetrexed	15%	Gefitinib	19%		
Kelly, 2012	Pralatrexate	32%	Erlotinib	32%		
KEYNOTE-010,2015	Pembrolizumab	34%	Docetaxel	35%		
Kim A, 2012	Pemetrexed+Cetuximab	41%	Pemetrexed	30%		

Kim B, 2012	Docetaxel+Cetuximab	53%	Docetaxel	40%		
Kuo, 2013	Docetaxel	17%	Gefitinib	25%		
Lee, 2013	Pemetrexed+Erlotinib	33%	Pemetrexed	29%	Erlotinib	22%
Li, 2014	Erlotinib	7%	Pemetrexed	5%		
LUME-COLUMBUS,2016	Docetaxel+Nintedanib	50%	Docetaxel	50%		
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	34%	Docetaxel	31%		
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	30%	Pemetrexed	33%		
Lux-Lung 8, 2015	Afatinib	39%	Erlotinib	38%		
Maitland, 2014	Pemetrexed+Cetuximab	30%	Cetuximab	55%		
MARQUEE, 2013	Erlotinib+Tivantinib	42%	Erlotinib	37%		
MARVEL, 2013	Erlotinib	0%	Pemetrexed	0%		
Moran, 2014	Erlotinib+Dalotuzumab	51%	Erlotinib	58%		
NCCTG N0626, 2011	Pemetrexed+Sorafenib	28%	Pemetrexed	14%		
NCIC CTG BR.26, 2014	Dacomitinib	40%	Placebo	36%		
OAK,2016	Atezolizumab	32%	Docetaxel	31%		
POPLAR, 2016	Atezolizumab	35%	Docetaxel	34%		
PROSE, 2014	Chemotherapy	2%	Erlotinib	3%		
Ramalingam, 2011	Erlotinib+R1507	25%	Erlotinib	14%		
Ramalingam, 2012	Dacomitinib	37%	Erlotinib	32%		
Ramlau, 2012	Docetaxel+Aflibercept	48%	Docetaxel	35%		
REVEL, 2014	Docetaxel+Ramucirumab	45%	Docetaxel	45%		
Scagliotti, 2012	Erlotinib+Sunitinib	44%	Erlotinib	38%		
Scagliotti, 2014	Erlotinib+Figitumumab	71%	Erlotinib	53%		
Schiller, 2010	Pemetrexed+Matuzumab	23%	Pemetrexed	18%		
SELECT 1,2017	Docetaxel+Selumetinib	49%	Docetaxel	32%		
Spigel, 2012	Erlotinib+Pazopanib	35%	Erlotinib	28%		
Spigel, 2013	Erlotinib+Onartuzumab	42%	Erlotinib	33%		
Sun, 2013	Docetaxel	8%	Pemetrexed	5%		
TAILOR, 2013	Docetaxel	4%	Erlotinib	2%		

TALISMAN, 2015	Docetaxel+Erlotinib	27%	Erlotinib	42%		
TITAN, 2012	Chemotherapy	15%	Erlotinib	10%		
V15-32, 2008	Gefitinib	17%	Docetaxel	14%		
Witta, 2012	Entinostat+Erlotinib	49%	Erlotinib	46%		
ZEAL, 2011	Pemetrexed+Vandetanib	32%	Pemetrexed	34%		
ZEST, 2011	Vandetanib	22%	Erlotinib	18%		
ZODIAC, 2010	Docetaxel+Vandetanib	38%	Docetaxel	34%		
<i>Fandi, 2018</i>	<i>CC-486 + Pembrolizumab</i>	<i>61%</i>	<i>placebo + Pembrolizumab</i>	<i>55%</i>		
<i>SELECT-2, 2017</i>	<i>Selumetinib + docetaxel 60</i>	<i>48%</i>	<i>Selumetinib + docetaxel 75</i>	<i>45%</i>	<i>Placebo + docetaxel 75</i>	<i>37%</i>
<i>Wu, 2017</i>	<i>Nab-paclitaxel</i>	<i>35%</i>	<i>Placebo</i>	<i>9%</i>		
<i>JAVELIN, 2018</i>	<i>Avelumab</i>	<i>9%</i>	<i>Docetaxel</i>	<i>21%</i>		
<i>ABOUND 2L+, 2018</i>	<i>Nab-Paclitaxel+CC-486</i>	<i>38%</i>	<i>Nab-Paclitaxel</i>	<i>37%</i>		